Monash IVF Warns of Sharp FY27 Profit Fall
The fertility group flagged weaker treatment demand and rising costs, and declined to issue a numerical profit forecast.
Updated on Nov. 20, 2026 in Healthcare

Live Poll
Have you or someone you know delayed fertility treatment this year?
Monash IVF Group warned its FY27 underlying net profit after tax will fall materially below FY26 and analyst consensus. The company declined to give a numerical forecast, citing uncertainty over demand.
Why it matters
Weaker market activity and rising costs for occupancy, wages, insurance and supplies are weighing on earnings across Australia's fertility sector. New facilities are also incurring costs before reaching expected activity levels.
Monash IVF's 12-month rolling market share held at 19.4% while industry stimulated cycles fell 0.5% over the same measure, against a 3.2% quarterly drop in Australian cycles. The group targets $8-11 million in annualised pre-tax savings from its productivity program, but has not said when those savings will fully flow through.
The players
Monash IVF Group
Monash IVF Group is an Australian fertility services provider that operates clinics and laboratories across the country and is listed on the Australian Securities Exchange.
The details
Monash IVF attributed the outlook to softer market activity, new local competition that eroded its position in South Australia, and a temporary closure of its Brisbane operations for about a month in July during a move to a new facility. Surgical volumes at Cremorne rose 22% between the fourth and first quarters.
Timeline
July: Brisbane operations closed temporarily for about a month during relocation.
First quarter of FY27: Stimulated treatment cycles fell 3.2% compared with the prior quarter.
October and November: Earnings performance lifted above first-quarter levels.
End of the second quarter of FY27: Brisbane facility expected to reach a steady operating level.
December 2026: New Clayton facility scheduled to open to patients.
Season Trajectory
The warning signals that Monash IVF's FY27 earnings will fall materially below FY26, a break from the prior year's trajectory. The company's market share has held steady, so the pressure is coming from lower treatment volumes and higher operating costs rather than lost ground to rivals.
Patients considering fertility treatment in Australia may face changing clinic availability, including the temporary Brisbane closure and the new Clayton facility opening in December 2026. Existing treatment pricing and out-of-pocket costs were not addressed in the source material.
The takeaway
Earnings in the fertility sector are being squeezed by softer treatment volumes and rising costs at the same time as new facilities ramp up. Investors and patients alike should watch whether productivity savings and facility utilisation improve over the coming quarters.
Further reading
For more on the sector, see the Healthcare coverage on Wisevoter.
Source note: This article includes information reported by Small Caps.
Live Poll
Have you or someone you know delayed fertility treatment this year?






